SK bioscience is a South Korean biotechnology company specialising in the research, development, and manufacture of vaccines, with a focus on global partnerships and contract manufacturing services.

Established in 2018 as a spin-off from SK Chemicals, SK bioscience has rapidly positioned itself as a key player in the global vaccine industry. Headquartered in Seongnam-si, South Korea, the company operates with a mission to promote human health from prevention to cure. Leveraging its advanced R&D capabilities and state-of-the-art manufacturing facilities, SK bioscience has developed a diverse portfolio of vaccines and has engaged in numerous international collaborations to enhance vaccine accessibility worldwide.

Key Products and Services:

In-house Vaccine Development and Manufacturing:

SKYCellflu® Quadrivalent: A cell culture-based influenza vaccine.

SKYZoster®: A live attenuated shingles vaccine.

SKYVaricella®: A varicella vaccine prequalified by the WHO.

SKYTyphoid®: A typhoid conjugate vaccine with WHO prequalification.

SKYCovione™: South Korea's first domestically developed COVID-19 vaccine.

Global Co-development and Technology Transfer:

Collaborations with international organisations and pharmaceutical companies, including Sanofi Pasteur, the Bill & Melinda Gates Foundation, and PATH, to co-develop next-generation vaccines.

Contract Development and Manufacturing Organisation (CDMO) Services:

Comprehensive CDMO services encompassing process development, clinical batch production, scale-up studies, and commercial manufacturing.

Capabilities include upstream and downstream processing, fill-finish operations, and quality control for viral and bacterial vaccines.

Strategic Investments and Acquisitions:

Acquisition of a controlling stake in IDT Biologika, a German CDMO specialising in viral vaccines and cell and gene therapies.

Investment in Fina Biosolutions, a U.S.-based biotech firm focused on conjugate vaccine technology.

Through its robust vaccine portfolio, strategic global partnerships, and comprehensive CDMO services, SK bioscience continues to play a pivotal role in addressing global health challenges. The company's commitment to innovation and collaboration positions it as a significant contributor to the advancement of public health worldwide.